Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells
Phase 1
27
about 1.7 years
18+
Female only
1 site in NC
About this study
This trial is testing the safety and tolerability of a new treatment called autologous T lymphocyte chimeric antigen receptor cells against the B7-H3 antigen (iC9-CAR.B7-H3 T cells) in patients with ovarian cancer that has returned after standard therapy. The iC9.CAR.B7-H3 treatment is experimental and has not been approved by the Food and Drug Administration. It team wants to determine a safe dose of the iC9-CAR.B7-H3 T cells, without causing too many side effects.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive iC9-CAR.B7-H3 T cells
- 2.Take Cyclophosphamide
- 3.Take Fludarabine
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), fludarabine
infusion
Primary: Toxicity: Cytokine Release Syndrome (CRS), Toxicity: Immune effector cell-associated neurotoxicity syndrome (ICANS), Toxicity: NCI-CTCAE
Secondary: Overall Survival (OS), Progression Free Survival (PFS), The disease control rate (DCR)
Oncology